The metastasis suppressor protein NM23-H1 modulates the PI3K-AKT axis through interaction with the p110α catalytic subunit.


Journal

Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004

Informations de publication

Date de publication:
30 Apr 2021
Historique:
received: 23 09 2020
accepted: 09 04 2021
revised: 05 03 2021
entrez: 1 5 2021
pubmed: 2 5 2021
medline: 2 5 2021
Statut: epublish

Résumé

The PI3K pathway is one of the most deregulated pathways in cancer, which is predominantly due to gain of function mutations or altered expression of the PI3KCA gene. This is codified by what is seen for the class I PI3K catalytic subunit p110α, a common feature of many cancers. The metastasis suppressor protein NM23-H1 (NME1), whose ability to suppress the metastasis activities of different tumors has been widely described and was previously reported to alter phosphatidylinositol signaling. Here, we show interaction of NM23-H1 with the p110α subunit and the functional consequence of this interaction. This interaction is predominantly localized at the plasma membrane with some signals seen in the cytoplasmic compartment. Analysis of NM23-H1 levels showed a negative correlation between NM23-H1 expression and Akt phosphorylation, the key marker of PI3K pathway activation. Investigating the functional consequence of this interaction using cell motility and clonogenicity assays showed that expression of NM23-H1 reversed the enhanced migration, invasion, adhesion, and filopodia structure formation in cells expressing the p110α catalytic subunit. A similar trend was seen in anchorage-independent assays. Notably, differential analyses using NM23-H1 mutants which lacked the enzymatic and metastasis suppressor activity, showed no detectable interaction between p110α and the NM23-H1 mutant proteins P96S, H118F, and S120G, as well as no dysregulation of the PI3K-AKT axis.

Identifiants

pubmed: 33931587
doi: 10.1038/s41389-021-00326-x
pii: 10.1038/s41389-021-00326-x
pmc: PMC8087825
doi:

Types de publication

Journal Article

Langues

eng

Pagination

34

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016520
Pays : United States
Organisme : Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
ID : R01-CA177423
Organisme : Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
ID : P01-CA174439
Organisme : Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
ID : P30-CA016520

Références

J Biol Chem. 1997 Feb 28;272(9):5525-32
pubmed: 9038158
J Natl Cancer Inst. 1988 Apr 6;80(3):200-4
pubmed: 3346912
PLoS Pathog. 2013;9(5):e1003314
pubmed: 23658517
Cancer Res. 2010 Oct 1;70(19):7710-22
pubmed: 20841469
Genetics. 1956 Jan;41(1):118-23
pubmed: 17247604
Cancer Res. 2007 Dec 15;67(24):11751-9
pubmed: 18089805
J Biol Chem. 2000 Feb 11;275(6):3741-4
pubmed: 10660520
Biochem Biophys Res Commun. 2003 Jul 25;307(2):281-9
pubmed: 12859952
Oncogene. 2008 Oct 27;27(50):6473-88
pubmed: 18955974
J Virol. 2005 Feb;79(3):1559-68
pubmed: 15650182
Cancer Res. 2013 Oct 1;73(19):5949-62
pubmed: 23940300
Cell. 1991 Apr 5;65(1):25-35
pubmed: 2013093
Clin Exp Metastasis. 2008;25(2):131-8
pubmed: 18058029
Curr Biol. 1997 Oct 1;7(10):776-89
pubmed: 9368760
Int J Oncol. 2008 Nov;33(5):959-67
pubmed: 18949358
Cell Adh Migr. 2011 Sep-Oct;5(5):421-30
pubmed: 21975551
Cell Death Discov. 2015 Oct 19;1:15044
pubmed: 27551473
J Clin Pathol. 2015 Apr;68(4):253-7
pubmed: 25688137
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11381-6
pubmed: 20534549
Naunyn Schmiedebergs Arch Pharmacol. 2011 Oct;384(4-5):331-9
pubmed: 21611737
Naunyn Schmiedebergs Arch Pharmacol. 2015 Feb;388(2):207-24
pubmed: 25199839
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Oncogene. 2009 Aug 6;28(31):2796-805
pubmed: 19483725
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10912-10917
pubmed: 28973861
Nat Med. 2001 Mar;7(3):350-5
pubmed: 11231635
Science. 1998 Jan 30;279(5351):710-4
pubmed: 9445477
Nature. 2008 May 29;453(7195):662-6
pubmed: 18449193
Cancer Biol Ther. 2008 May;7(5):677-88
pubmed: 18728402
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
Crit Rev Oncol Hematol. 2011 Nov;80(2):278-90
pubmed: 21316260
Cell. 2011 Nov 23;147(5):992-1009
pubmed: 22118458
Nat Rev Mol Cell Biol. 2010 May;11(5):329-41
pubmed: 20379207
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Clin Exp Metastasis. 1998 Oct;16(7):595-602
pubmed: 9932606
Science. 1997 Jul 25;277(5325):567-70
pubmed: 9228007
Nat Rev Cancer. 2005 Dec;5(12):921-9
pubmed: 16341083
Cell Signal. 2012 Feb;24(2):514-523
pubmed: 22019461
J Natl Cancer Inst. 2005 May 4;97(9):632-42
pubmed: 15870434
Oncogene. 2005 Apr 28;24(19):3154-65
pubmed: 15735674
Int J Cell Biol. 2010;2010:507821
pubmed: 20671957
Curr Biol. 1997 Apr 1;7(4):261-9
pubmed: 9094314
Mol Cell Biol. 1996 Aug;16(8):4117-27
pubmed: 8754810
Nature. 1994 Aug 4;370(6488):335-6
pubmed: 8047138
PLoS Pathog. 2017 Jul 24;13(7):e1006500
pubmed: 28738086

Auteurs

Francesco Paolo Pennino (FP)

Department of Otorhinolaryngology-Head and Neck Surgery, Perelman School of Medicine, Tumor Virology Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

Masanao Murakami (M)

Health Sciences Department of Medical Laboratory Science, Kochi Gakuen University, Nankoku, Kochi, Japan.

Massimo Zollo (M)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche DMMBM, Universita' di Napoli Federico II, Naples, Italy.
CEINGE Biotecnologie Avanzate, Naples, Italy.
European School of Molecular Medicine, SEMM, University of Milan, Milan, Italy.

Erle S Robertson (ES)

Department of Otorhinolaryngology-Head and Neck Surgery, Perelman School of Medicine, Tumor Virology Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. erle@upenn.edu.
Tumor Virology Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. erle@upenn.edu.

Classifications MeSH